SyntekaBio, Inc. presented the result of STB-C017 animal experiments, a small molecule IDO/TDO dual inhibitor derived by Syntekabio's AI drug discovery solution, at the 2020 American Association for Cancer Research (AACR) Annual Meeting. The presentation with key findings is titled 'Artificial intelligence with a deep learning technology enables a rational development of a potent immunotherapeutic agent,' and includes: STB-C017 effectively blocked kynurenine secretion from tumor, an immunosuppressor, and showed dose-response relationship in colorectal cancer mice models; STB-C017 treatment showed significant infiltrations of CD8+ T cells into the tumor, and reduction of Treg Cells; STB-C017 dosing regimen optimized as 5 days of administration & 2 days off; Combination therapy with anti-PD1/CTLA4 markedly delayed tumor growth and induced multiple CRs.: STB-C017 triple combination induced two-fold increase of CRs compared to epacadostat triple. Recovered mice acquired long-term antineoplastic immunity; Mice treated with STB-C017 triple combination showed marked survival benefit compared to the others, including epacadostat triple. Syntekabio plans subsequent STB-C017 development, including GLP toxicology and animal PKPD, targeting IND submission, around 1H 2022. The company will execute further translational research based on firm collaboration with CHA Bundang Hospital and lead the full scope of the development programs.